pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Australia
Bristol-Myers Squibb Australia Pty Ltd
Bristol-Myers Squibb Australia is a pharma organization headquartered in Melbourne, AU. Primary therapeutic focus areas include Advanced Solid Tumors, Agitation Associated with Alzheimer’s Disease, BP-I mania or mania wi
Company details
- Status
- Public
- HQ
- PO Box 1080, Mount Waverley, Victoria 3149, Australia
- Employees
- 6
- Programs
- 93
- Drugs
- 120
- Patents
- 0
CA180-226
Phase 2 · small molecule · Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib
CA180-226 for Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib is a Phase 2 program (small_molecule) at Bristol-Myers Squibb Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code CA180-226
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bristol-Myers Squibb Australia Pty Ltd
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib
- Status
- active
- Trials
- 1